Omid Veiseh: First-in-Human Clinical Trial of IL-2 Cytokine Factories in Refractory Ovarian Cancer
oncodaily - Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn: “Excited to publish the results […]
AI Summary: A first‑in‑human trial of implantable IL‑2 “cytokine factories” in refractory ovarian cancer reported encouraging early safety and biological activity, offering a localized immune‑stimulation strategy that may boost tumor responses while avoiding systemic toxicity. Investigators described the device‑based platform as a potential option for patients with limited alternatives, pending larger efficacy studies.
Related Stories
Merck and Moderna report positive phase‑3 melanoma vaccine results / 10 days
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 12 days
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 22 days
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 5 wks
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 1 month
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 2 months
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pediatric Oncology, Novo Nordisk, Supplements, Medical Devices and look for the RSS link.
StackHealth Time Machine